This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Flunixin
DrugBank Accession Number
DB11518
Background

Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian. Flunixin may be also referred to as Banamine, and other trade names.

Type
Small Molecule
Groups
Vet approved
Structure
Thumb
Weight
Average: 296.249
Monoisotopic: 296.077262091
Chemical Formula
C14H11F3N2O2
Synonyms
  • 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylic acid
  • Flunixin
  • Flunixine
  • Flunixino
  • Flunixinum
External IDs
  • SCH 14714

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirFlunixin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Abciximab.
AcebutololFlunixin may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flunixin.
AcemetacinThe risk or severity of adverse effects can be increased when Flunixin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Flunixin.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Flunixin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Flunixin.
AclidiniumFlunixin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Flunixin meglumine8Y3JK0JW3U42461-84-7MGCCHNLNRBULBU-WZTVWXICSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Pyridinecarboxylic acids / Aniline and substituted anilines / Toluenes / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines / Azacyclic compounds
show 8 more
Substituents
Alkyl fluoride / Alkyl halide / Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Carboxylic acid
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, aminopyridine, pyridinemonocarboxylic acid (CHEBI:76138)
Affected organisms
Not Available

Chemical Identifiers

UNII
356IB1O400
CAS number
38677-85-9
InChI Key
NOOCSNJCXJYGPE-UHFFFAOYSA-N
InChI
InChI=1S/C14H11F3N2O2/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12/h2-7H,1H3,(H,18,19)(H,20,21)
IUPAC Name
2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid
SMILES
CC1=C(C=CC=C1NC1=C(C=CC=N1)C(O)=O)C(F)(F)F

References

General References
  1. Webbon PM, Woolliscroft GJ: Cautious use of flunixin advocated. Vet Rec. 1984 Jul 14;115(2):45. [Article]
  2. Dobromylskyj P: Intraoperative use of flunixin meglumine. Vet Rec. 1992 Nov 28;131(22):520. [Article]
  3. Elwood C, Boswood A, Simpson K, Carmichael S: Renal failure after flunixin meglumine administration. Vet Rec. 1992 Jun 27;130(26):582-3. [Article]
  4. Traub-Dargatz JL, Bertone JJ, Gould DH, Wrigley RH, Weiser MG, Forney SD: Chronic flunixin meglumine therapy in foals. Am J Vet Res. 1988 Jan;49(1):7-12. [Article]
  5. Hardie EM, Kolata RJ, Rawlings CA: Canine septic peritonitis: treatment with flunixin meglumine. Circ Shock. 1983;11(2):159-73. [Article]
  6. Jaussaud P: [Flunixin and its use in horses]. Ann Rech Vet. 1986;17(4):353-62. [Article]
  7. Hardie EM, Hardee GE, Rawlings CA: Pharmacokinetics of flunixin meglumine in dogs. Am J Vet Res. 1985 Jan;46(1):235-7. [Article]
  8. Ciofalo VB, Latranyi MB, Patel JB, Taber RI: Flunixin meglumine: a non-narcotic analgesic. J Pharmacol Exp Ther. 1977 Mar;200(3):501-7. [Article]
  9. Hardee GE, Smith JA, Harris SJ: Pharmacokinetics of flunixin meglumine in the cow. Res Vet Sci. 1985 Jul;39(1):110-2. [Article]
  10. Smitherman P: Intra-operative use of flunixin meglumine. Vet Rec. 1992 Nov 14;131(20):471. [Article]
KEGG Drug
D04215
ChemSpider
34911
BindingDB
50201618
RxNav
25121
ChEBI
76138
ChEMBL
CHEMBL1617398
ZINC
ZINC000000001467
Wikipedia
Flunixin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0402 mg/mLALOGPS
logP4.17ALOGPS
logP3.69ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)1.88ChemAxon
pKa (Strongest Basic)5.38ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity70.97 m3·mol-1ChemAxon
Polarizability26.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0002-0090000000-70f9b31983f5288b8fea
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-92c4d99935c961396ae7
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0090000000-080bf40f3dcf0daaa83d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0lyo-0390000000-f93dbab44765f08c0dab
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-052f-0980000000-25f1566c97820e3a4a2e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-052f-0940000000-9954d8a5607714ddf5b8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-1900000000-ccf143a90e816a424dc8
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01p9-4900000000-964033ab162c6602211d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03dr-9600000000-c91aeffcb76d5deb5560
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-6c7e03b24bf5feb5651e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0090000000-ae48aa44e601b23f0084
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0090000000-7c0fde19ae2a2a9c41e3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03fr-0090000000-17b52355cf235bfb3cc6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0290000000-af8ac4c2148d16e2d6f1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-1a92e6dc858763eada2d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-db80fa85855c5a1b0ea6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0090000000-6f29eea19f1a0079312e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01t9-0090000000-e441a6cc43bcb96a91e6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0290000000-54c443792e065716310d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0bti-0790000000-07ca5cb6f169826c16fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-2920000000-bbf4b2222726f83a7484
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a5a-5900000000-2aec522ff8dac4251203
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-06rt-9600000000-2ffd8bd220d0979b5244

Drug created at February 26, 2016 17:31 / Updated at February 21, 2021 18:53